This segment focuses on providing contract research services to pharmaceutical and biotechnology companies, specializing in proteomics and biomarker identification. Proteome Sciences utilizes advanced mass spectrometry techniques, including TMT and TMTpro technologies, to analyze proteins and identify potential drug targets and biomarkers. Research and development activities include the continuous improvement of TMT technologies and the development of new assays for various applications. The company offers services for biomarker discovery, validation, and application in areas such as oncology, neurology, and other therapeutic areas. The impact on patients is through accelerating drug discovery and development, leading to more effective and targeted therapies. Proteome Sciences' market positioning is as a specialist provider with proprietary technologies, offering a competitive advantage in quantitative proteomics. Future opportunities include expanding service offerings and geographic reach, particularly in the US market. Regulatory and clinical aspects are crucial, as the company's services support clinical trials and drug development processes. Partnerships with companies like Thermo Fisher Scientific and CHDI Foundation demonstrate the company's collaborative approach.

This segment concentrates on the identification, validation, and application of protein biomarkers for various diseases. Proteome Sciences employs advanced proteomics techniques, including TMT-based methods, to analyze complex biological samples like plasma and tissues. Research and development efforts are focused on improving the sensitivity, accuracy, and throughput of biomarker assays. The company offers services such as SysQuant for pathway analysis, TMT MS2 and MS3 for quantitative proteomics, and TMT SRM for targeted biomarker validation. These services support drug discovery, diagnostics, and personalized medicine initiatives. The therapeutic areas covered include oncology, neurology, and other disease areas where biomarkers can aid in diagnosis, prognosis, and treatment monitoring. The patient impact is significant, as validated biomarkers can lead to earlier disease detection, improved treatment selection, and better patient outcomes. Proteome Sciences' competitive advantage lies in its proprietary TMT technology and expertise in quantitative proteomics. Future opportunities include expanding into new therapeutic areas and developing companion diagnostics. Regulatory aspects are critical, as biomarker assays must meet stringent requirements for clinical use. Collaborations with pharmaceutical companies and research institutions are essential for advancing biomarker research and translating discoveries into clinical applications.